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Abstract
Susceptibility pattern of 45 Campylobacter spp.isolates – 16 C. jejuni, eight C. coli, and 21 C. fetus isolated from different 
animal species in Brazil – to twelve antimicrobial agents was determined. All Campylobacter spp. isolates were susceptible 
to gentamicin, sulfadiazine, and sulfamethoxazole. C. jejuni and C. coli were also sensitive to chloramphenicol, whereas 
all C. fetus strains were susceptible to kanamycin. Cefoperazone showed the highest percentage of resistance among C. 
jejuni (68.75%), followed by nalidixic acid (31.25%), ampicillin (37.50%), tetracycline (37.50%), erythromycin (12.50%), and 
kanamycin (6.25%). Likewise, cefoperazone exhibited the highest percentage of resistance among C. coli (75.00%), followed 
by nalidixic acid (50.00%), tetracycline (50.00%), erythromycin (37.50%), ampicillin (12.50%), and kanamycin (12.50%). 
Among C. fetus strains, nalidixic acid showed the highest resistance rate (85.71%), followed by cefoperazone (71.43%), 
tetracycline (42.86%), ampicillin (19.05%), chloramphenicol (9.52%), and erythromycin (4.76%). Therefore, it was found 
that the majority of Campylobacter spp. isolated from animals was sensitive to gentamycin, chloramphenicol, kanamacyn, 
and sulfonamides; however, a high proportion of the strains showed reduced susceptibility to nalidixic acid, ampicillin, 
cefoperazone, and tetracycline. Moreover, C. coli and C. fetus isolates showed a high percentage of multidrug resistant strains.
Keywords: Antimicrobial drug resistance. Campylobacter spp.. Brazil. Cattle. Pigs. Broilers. Marmosets. Dogs.
Resumo
O padrão de sensibilidade de 45 amostras de Campylobacter spp, incluindo 16 amostras de C. jejuni, 8 de C. coli e 21 C. 
fetus, isoladas de diferentes espécies de animais do Brasil, foi determinado para doze antimicrobianos. Todas as amostras de 
Campylobacter spp foram sensíveis à gentamicina, sulfadiazina e sulfametoxazol. C. jejuni e C. coli foram também sensíveis 
ao cloranfenicol, enquanto todas as amostras de C. fetus foram sensíveis à canamicina. Cefoperazona mostrou o maior 
percentual de resistência entre C. jejuni (68,75%), seguido pelo ácido nalidíxico (31,25%), ampicilina (37,50%), tetraciclina 
(37,50%), eritromicina (12,50%) e canamicina (6,25%). Similarmente, cefoperazona também exibiu o maior percentual de 
resistência entre as amostras de C. coli (75,00%), seguido pelo ácido nalidíxico (50,00%), tetraciclina (50,00%), eritromicina 
(37,50%), ampicilina (12,50%) e canamicina (12,50%). Entre os isolados de C. fetus, ácido nalidíxico apresentou maior 
taxa de resistência (85,71%), seguido de cefoperazona (71,43%), tetraciclina (42,86%), ampicilina (19,05%), cloranfenicol 
(9,52%) e eritromicina (4,76%). Assim, os nossos resultados mostraram que a maioria das amostras de Campylobacter spp 
isolados de animais foram sensíveis à gentamicina, cloranfenicol, canamicina e sulfonamidas. No entanto, uma proporção 
elevada das amostras apresentou susceptibilidade reduzida ao ácido nalidíxico, ampicilina, cefoperazona e tetraciclina. 
Além disso, C. coli e C. fetus mostraram uma alta porcentagem de amostras resistentes a múltiplas drogas.
Palavras-chave: Resistência a antimicrobianos. Campylobacter spp.. Brasil. Bovinos. Suínos. Frangos. Saguis. Cães.
Introduction
Campylobacter spp. are Gram-negative, non-
spore forming, microaerophilic, curved or spiral rods 
responsible for important diseases in human and animals 
(DEBRUYNE et al., 2008) C. jejuni and C. coli are some 
of the major culture-confirmed bacteria associated with 
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human gastroenteritis in the United States (CDC, 2013), 
and C. fetus subsp. fetus and C. fetus subsp. venerealis 
are important livestock pathogens, besides being human 
pathogens (ALVES et al., 2011).
Attention to Campylobacter infections has increased 
since they were recognized in 1970’s as important 
human pathogens and public health issue, especially 
C. jejuni and, to a lesser extent, C. coli. (OLSON et al., 
2008; CDC, 2013) Although the majority of the human 
cases of Campylobacter spp. gastroenteritis are related to 
self-limited diarrhea, severe sequels as reactive arthritis 
and Guillain-Barré syndrome may sporadically occur 
(OLSON et al., 2008). Humans are infected by C. jejuni 
or C. coli mainly through direct contact with carrier 
animals or consumption of contaminated food and water, 
poorly processed poultry meat and non-pasteurized milk 
(OLSON et al., 2008). C. fetus is a rare human pathogen 
frequently involved in systemic and extra-intestinal disease 
in patients with preexisting illnesses (WOO et al., 2002). 
In contrast to the secondary role in human infections, C. 
fetus is an important cause of abortion and infertility in 
cattle, being responsible for great economic losses (ALVES 
et al., 2011). Moreover, bacteria of the genus Campylobacter 
can be isolated from several domestic and wildlife animal 
species, as commensal microorganisms or causing a large 
number of non-reproductive diseases such as enteritis and 
mastitis (DEBRUYNE et al., 2008).
Antimicrobial treatment of human campylobacteriosis 
is usually not needed; however, for severe or long-lasting 
cases and for systemic infections it becomes mandatory 
(ADVICE FOR TRAVELERS, 2012). Erythromycin and 
azithromycin are the drugs of choice to treat C. jejuni 
and C. coli gastrointestinal infections in humans, but 
fluoroquinolones and tetracyclines are also recommended 
(ADVICE FOR TRAVELERS, 2012; DEKATE et al., 
2013). The optimal treatment regimen for human C. fetus 
infection has not been determined, but gentamicin and 
imipenem are suggested as empirical therapy of choice and 
ampicilin, chloramphenicol, and fluoroquinolones could 
also be considered (TREMBLAY et al., 2003).
The resistance of Campylobacter spp. isolates, from both 
humans and animals, to different classes of antimicrobial 
agents such as quinolones, macrolides, aminoglycosides, 
tetracyclines, β-lactams, and sulfonamides has been widely 
reported (VAN DEN BOGAARD; STOBBERINGH, 2000; 
CHUMA et al., 2001; AVRAIN et al., 2003; TREMBLAY 
et al., 2003; MIRANDA; LAGE, 2007; ABAY et al., 2014; 
DI GIANNATALE et al., 2014). Nonetheless, mainly 
the resistance to quinolones and macrolides has been 
considered an emerging public health hazard, due to its 
fast increase in the last decades (GIBREEL; TAYLOR, 
2006; FITZGERALD et al., 2008; GARCIA-MIGURA 
et al., 2014). The high incidence of antibiotic resistance 
among Campylobacter spp. has led to an intensification of 
the discussion over the rational use of antimicrobial agents, 
especially in veterinary medicine, since their massive use, 
mainly as feed additives, has been related to the increase of 
drug resistance in Campylobacter spp. (JUNTUNEN et al., 
2011; GARCIA-MIGURA et al., 2014; USUI et al., 2014).
Thus, the aim of the present study was to determine the 
antimicrobial susceptibility profile of 45 Campylobacter 
spp. isolates from different animal species in the State of 
Minas Gerais, Brazil.
Materials and Methods
Bacterial strains and culture conditions
A total of 45 Campylobacter spp. were used – 16 
C. jejuni, eight C. coli, and 21 C. fetus strains from the 
collection of Laboratório de Bacteriologia Aplicada, Escola 
de Veterinária, Universidade Federal de Minas Gerais 
(UFMG) and Departamento de Microbiologia, Instituto 
de Ciências Biológicas, UFMG, isolated between 1977 
and 2000 (LEITE, 1977; CARVALHO, 1992; LAGE, 1992; 
LAGE et al., 1992; STYNEN et al., 2003). C. jejuni strains 
were isolated from feces or rectal swabs of dogs (n = 5), 
marmosets (n = 5), pigs (n = 3), broilers (n = 2), and calf (n 
= 1). C. coli strains were isolated from feces or rectal swabs 
of pigs (n = 6), broiler (n = 1), and calf (n = 1). C. fetus 
strains were isolated from feces of calves (n = 14) or from 
genital tract (n = 7) of adult cattle. All strains were isolated 
from animals from Minas Gerais, Brazil, and identified 
through routine laboratory methods (DEBRUYNE et al., 
2008).
Campylobacter spp. isolates were cultured in brain heart 
infusion (BHI) agar (Difco, USA) supplemented with 10% 
of defibrinated horse blood and incubated for 48 h at 37°C 
under microaerophilic conditions (10% CO2, 5% O2, 85% 
N2) (DEBRUYNE; GEVERS; VANDAMME, 2008).
Antimicrobial susceptibility testing
Minimum Inhibitory Concentration (MIC) was 
determined according to the Clinical and Laboratory 
Standards Institute (CLSI) VET01-A4 manual 
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recommendations (CLSI, 2013a) for ampicillin (Life 
Technologies, Carlsbad, CA, USA), cefoperazone 
(Pfizer, New York, NY, USA), chloramphenicol (Life 
Technologies, Carlsbad, CA, USA), erythromycin 
(Gerbrás, Anápolis, GO, Brazil), gentamicin (Inlab, 
São Paulo, SP, Brazil), kanamycin (Inlab, São Paulo, 
SP, Brazil), nalidixic acid (Inlab, São Paulo, SP, Brazil), 
penicillin G (Inlab, São Paulo, SP, Brazil), streptomycin 
(Merck, Darmstadt, HE, Germany), sulfadiazine (Inlab, 
São Paulo, SP, Brazil), sulfamethoxazole (Sigma-Aldrich, 
St. Louis, MO, USA), and tetracycline (Inlab, São Paulo, 
SP, Brazil) in a dilution ranging from 0.0625 to 256 µg/
mL. Briefly, Mueller-Hinton agar (Difco, Sparks, MD, 
USA) plates supplemented with 5% defibrinated horse 
blood plus the antimicrobial were inoculated with 
bacterial suspensions adjusted to turbidity equivalent to 
a 0.5 McFarland standard and incubated for 48h at 37oC 
under microaerophilic conditions.
Determination of the MIC was performed in duplicate 
and all antibiotics were tested with the reference strains 
Escherichia coli ATCC 25922, Pseudomonas aeruginosa 
ATCC 27853, and C. jejuni NCTC 11351 to ensure that 
the results were within acceptable limits of quality control 
for susceptibility testing (CLSI, 2013b). Furthermore, 
two Mueller-Hinton agar plates supplemented with 
5% defibrinated horse blood, without antibiotics, were 
employed at the beginning of the antibiotic plate sequence, 
and two at the end of this sequence, as growth controls.
MIC breakpoints were set in accordance to the CLSI 
for C. jejuni / C. coli or Enterobacteriaceae (Table 1) 
(CHEN et al., 2010; CLSI, 2010, 2012, 2013b). Based on 
these criteria the strains were classified as resistant or 
sensitive to antimicrobials. However, the breakpoints to 
penicillin G and streptomycin were not defined by CLSI, 
and therefore the percentage of resistant strains could 
not be determined.
Table 1  – Minimal Inhibitory Concentration (MIC) breakpoints to determine antimicrobial susceptibility of Campylobacter spp. 
isolates
Antibiotic
MIC breakpoint Reference
Sa Ib Rc Document Strain
Nalidixic acid ≤ 8 - > 16 CA-SFMd C. jejuni / C. coli
Ampicillin ≤ 8 16 ≥ 32 CLSIe – VET01-S2 Enterobacteriaceae
Kanamycin ≤ 16 32 ≥ 64 CLSI – M100-S22 Enterobacteriaceae
Cefoperazone ≤ 16 32 ≥ 64 CLSI – M100-S22 Enterobacteriaceae
Chloramphenicol ≤ 8 16 ≥ 32 CLSI – VET01-S2 Enterobacteriaceae
Erythromycin ≤ 8 16 ≥ 32 CLSI – M45-A2 C. jejuni / C. coli
Gentamycin ≤ 2 4 ≥ 8 CLSI – VET01-S2 Enterobacteriaceae
Sulfadiazine ≤ 256 - ≥ 512 CLSI – VET01-S2 Enterobacteriaceae
Sulfamethoxazole ≤ 256 - ≥ 512 CLSI – VET01-S2 Enterobacteriaceae
Tetracycline ≤ 4 8 ≥ 16 CLSI – M45-A2 C. jejuni /C. coli
a Susceptible; b Intermediate; c Resistant; d Antibiogram Committee of the French Society for Microbiology; e Clinical and Laboratory Standards Institute
Multidrug resistance was defined as resistance to three or 
more antimicrobial classes. The antimicrobial classes were 
as follows: (i) quinolones (nalidixic acid); (ii) macrolides 
(erythromycin); (iii) tetracycline (tetracycline); (iv) 
β-lactams (penicillin G, cefoperazone, and ampicillin); (v) 
aminoglycosides (gentamicin, streptomycin, and kanamycin); 
(vi) sulfonamides (sulfamethoxazole and sulfadiazine); and 
(vii) phenicols (chloramphenicol). Strains resistant to three 
or more antimicrobial groups were considered multidrug 
resistant. (MAGIORAKOS et al., 2012)
Results
The MIC range, MIC50 and MIC90 found for the 45 
Campylobacter spp. studied strains, as well as the number 
of resistant strains to each antimicrobial agent tested are 
shown in figure 1.
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Figure 1 – Scatter plot of the Minimal Inhibitory Concentration (MIC) by the agar dilution method to nalidixic 
acid (N=A), ampicillin (AMP), kanamycin (KAN), cefoperazone (CPZ), chloramphenicol (CHL), 
erythromycin (ERY), streptomycin (STR), gentamycin (GEN), penicillin G (PENG), sulfadiazine 
(SSD), sulfamethoxazole (SMX), and tetracyclin (TET) of C. jejuni (n = 16), C. coli (n = 8), and C. fetus 
(n = 21) strains isolated from animals in the state of Minas Gerais, Brazil. Resistant strains are shown in 
red symbols and intermediate susceptibility profile in yellow symbols. The ellipses indicate the MIC50 
for each antimicrobial agent, while dotted rectangles indicate the MIC90
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All Campylobacter spp. strains tested were susceptible to 
gentamicin, sulfadizine, and sulfamethoxazole (Figure 1). C. 
jejuni strains were also 100% sensitive to chloramphenicol. 
Cefoperazone was the antimicrobial that presented the lowest 
activity, against C. jejuni, with 68.75% (11/16) of resistant 
strains, followed by nalidixic acid [31.25% (5/16)], ampicillin 
[37.50% (6/16)], tetracycline [37.50% (6/16)], erythromycin 
[12.50% (2/16)], and kanamycin [6.25% (1/16)] (Figure 1). 
Moreover, C. jejuni strains also exhibited an intermediate 
susceptibility profile to ampicillin [37.50% (6/16)].
As observed in C. jejuni, all tested C. coli strains exhibited 
sensitivity to chloramphenicol. The antibiotic with the lowest 
activity against C. coli was cefoperazone, with 75.00% (6/8) 
of resistant strains, followed by nalidixic acid [50.00% (4/8)], 
tetracycline [50.00% (4/8)], erythromycin [37.50% (3/8)], 
ampicillin [12.50% (1/8)], and kanamycin [12.50% (1/8)]. 
Furthermore, 50.00% (4/8) of C. coli strains also showed an 
intermediate susceptibility profile to ampicillin.
Among C. fetus strains, the highest percentage 
of resistance was observed to nalidixic acid [85.71% 
(18/21)], followed by cefoperazone [71.43% (15/21)], 
tetracycline [42.86% (9/21%)], ampicillin [19.05% (4/21)], 
chloramphenicol [9.52% (2/21)], and erythromycin [4.76% 
(1/21)]. Intermediate susceptibility patterns to ampicillin 
and cefoperazone were observed in 28.57% (6/21) and 
4.76% (1/21) of C. fetus strains, respectively. All C. fetus 
strains were susceptible to kanamycin.
The susceptibility profile of Campylobacter spp. strains 
tested for ten antimicrobials with established breakpoints 
is shown in table 2.
Table 2 – Antimicrobial susceptibility profile of Campylobacter spp. strains isolated from animals in the state of Minas Gerais, Brazil
Species NA AMP KAN CPZ CHL ERY GEN SSD SMX TET Nd Profilee
C. jejuni Ra Ib Sc R S S S S S R 1 1
C. jejuni S R S R S R S S S R 1 2
C. jejuni R S S R S R S S S S 1 3
C. jejuni S R S R S S S S S S 3 4
C. jejuni S I S R S S S S S R 2 5
C. jejuni S I S R S S S S S S 2 6
C. jejuni R S S S S S S S S S 1 7
C. jejuni S R S R S S S S S R 1 8
C. jejuni S I S S S S S S S S 1 9
C. jejuni R S R S S S S S S S 1 10
C. jejuni S R S S S S S S S S 1 11
C. jejuni R S S S S S S S S R 1 12
C. coli S I S R S R S S S R 1 1
C. coli R R R R S R S S S R 1 2
C. coli R S S R S S S S S R 1 3
C. coli S I S R S S S S S R 1 4
C. coli R S S R S S S S S S 1 5
C. coli S S S S S S S S S S 1 6
C. coli R I S S S S S S S S 1 7
C. coli S I S R S R S S S S 1 8
C. fetus R S S R S S S S S R 3 1
C. fetus R I S R S S S S S R 2 2
C. fetus R R S R S S S S S R 2 3
C. fetus R I S R R S S S S R 1 4
C. fetus S I S R S R S S S R 1 5
C. fetus R R S R R S S S S S 1 6
C. fetus R S S S S S S S S S 4 7
C. fetus R S S R S S S S S S 2 8
C. fetus R I S R S S S S S S 2 9
C. fetus R R S I S S S S S S 1 10
C. fetus S R S R S S S S R S 1 11
C. fetus S S S S S S S S S S 1 12
a Resistant b Intermediate; c Susceptible; d Number of strains; e Profile highlighted in bold italics showed resistance to three or more antimicrobial groups and were 
considered multidrug resistant
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Three [14.29% (3/21)] C. jejuni strains were multidrug 
resistant: two isolated from pigs and one from poultry. 
Among the observed multidrug-resistant C. coli strains 
[37.50% (3/8)], two were isolated from pigs and one from 
calf. C. fetus strains exhibited the highest percentage of 
multidrug-resistant strains [47.62% (10/21)]. Among C. 
fetus isolates from calf feces the percentage of multidrug 
resistant strains was 57.14% (8/14), whereas among the 
C. fetus isolated from genital tract 28.57% (2/7) were 
considered multidrug-resistant.
Discussion
The emergence of antibiotic resistance in Campylobacter 
spp. has been associated with the use of antimicrobials in 
veterinary medicine (THRELFALL et al., 2000; GARCIA-
MIGURA et al., 2014). Therefore, the present study 
investigated the susceptibility profile of C. jejuni, C. coli, 
and C. fetus isolated from different animal species in Minas 
Gerais, Brazil, to twelve antimicrobial agents, and observed 
that cefoperazone, nalidixic acid, and tetracycline were 
the antibiotics that exhibited the lowest activity against 
all Campylobacter spp. tested, whereas the highest rate 
of susceptible strains found was to chloramphenicol, 
gentamycin, sulfadiazine, and sulfamethoxazole.
Beta-lactam, including ampicillin and cefoperazone, 
was the antimicrobial class that showed the highest level 
of resistance among all Campylobacter spp. strains tested 
(Table 2). Since C. jejuni and C. coli spp. are universally 
resistant to cephalosporins (FITZGERALD et al., 2008) 
as well as cefoperazone, and this drug is regularly used 
in Campylobacter selective media (LAGE et al., 1992) to 
inhibit other bacteria, the excessive number of resistant 
strains to this antimicrobial was not an unexpected result; 
on the contrary, it confirms media with cefoperazone as a 
good choice for primary isolation of C. jejuni and C. coli. 
Furthermore, the high rate of resistance to cefoperazone 
also observed among C. fetus strains could be explained 
considering that all C. fetus strains isolated from feces 
samples were cultivated in medium containing this drug 
(LAGE et al., 1992), which is a surprising result, since 
C. fetus is not intrinsically resistant to cefoperazone. 
Reduced susceptibility, with a large number of resistant or 
intermediate patterns, especially amongst C. jejuni isolates, 
was also observed to ampicillin. Ampicillin resistance is of 
special clinical interest since this drug may be used for the 
treatment of severe human campylobacteriosis infections, 
particularly in children (GALLAY et al., 2007). C. jejuni 
and C. coli isolated from animals, mainly poultry, were 
broadly reported to be resistant to ampicillin (GALLAY et 
al., 2007; LEHTOPOLKU et al., 2010; ADZITEY et al., 2012; 
CHOKBOONMONGKOL et al., 2013; GIACOMELLI et 
al., 2014). Nevertheless, resistance to ampicillin among 
C. fetus strains has not been described, even for C. fetus 
isolated in the same region as the strains tested in the 
present study (Minas Gerais State, Brazil) (TREMBLAY 
et al., 2003; VARGAS et al., 2005; GALLAY et al., 2007; 
MIRANDA; LAGE, 2007). These differences are probably 
due to differences in the methodology used or in the origin 
of the strains, since a low-level agreement was observed 
for ampicillin in the comparison of agar dilution and agar 
disk diffusion methods (LUANGTONGKUM et al., 2007). 
Although there is no established breakpoint for penicillin 
G to Campylobacter spp., the wide range of MIC values 
observed as well as the high MIC50 and MIC90 values 
indicate a tendency to resistance to penicillin G among 
the tested C. jejuni, C. coli, and C. fetus strains (Figure 1). 
Moreover, a large number of those Campylobacter 
spp. strains were also resistant to other beta-lactams 
(cefoperazone and ampicillin), which strongly supports 
this trend of resistance to penicillin G, as the production of 
beta-lactamases is the dominant mechanism of resistance 
to beta-lactam drugs and they are widely reported in 
Campylobacter spp. (WIECZOREK; OSEK, 2013).
Nalidixic acid, together with beta-lactam drugs, was 
the drug with the highest rates of resistance among the 
studied Campylobacter spp. strains, especially C. fetus 
strains, which are naturally resistant to nalidixic acid 
(Figure 1) (BURNENS et al., 1993). This nalidixic acid 
resistance may indicate resistance to other quinolones 
such as ciprofloxacin, although it was not assessed in the 
present study, since for C. jejuni and C. coli nalidixic acid 
resistance correlates well with resistance to other quinolone 
drugs (KINANA et al., 2006). Resistance to quinolones 
amongst Campylobacter spp. is a global concern and has 
increased and spread very quickly (FITZGERALD et al., 
2008; GARCIA-MIGURA et al., 2014). Administration 
of quinolones, especially its subtherapeutic use in food 
animals, has been implicated as the force behind increase 
in resistance to quinolones in Campylobacter spp. isolates 
from humans and animals (JUNTUNEN et al., 2011; 
GARCIA-MIGURA et al., 2014; USUI et al., 2014). In 
Brazil, fluoroquinolones were used as growth-promoter, 
although this not allowed anymore, which could explain 
the great incidence of nalidixic acid resistant C. jejuni and 
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C. coli strains observed in the present study (PAMVET-PR, 
2005; SILVA; HOLLENBACH, 2010; SILVA et al., 2013). 
Moreover, this link is corroborated by poultry and pigs 
being, respectively, the main hosts of C. jejuni and C. coli, 
and quinolones being commonly use as feed additive in 
poultry and pork industries (PAMVET-PR, 2005; SILVA; 
HOLLENBACH, 2010).
Tetracycline was one of the three classes of antimicrobial 
drugs presenting the lowest activity against the tested 
Campylobacter spp. strains, with C. fetus strains showing 
the highest rate of resistance to it. This high level of resistance 
to tetracycline is probably a direct reflex of its intense use 
in veterinary medicine, especially in cattle (FDA, 2010). 
Indeed, cattle and sheep are the main hosts of C. fetus, which 
are found in the intestines of heathy animals and abundantly 
in their genital tract (LASTOVICA; ALLOS, 2008). The 
increase in resistance rates to tetracyclines of Campylobacter 
spp. is worrisome and has been constantly described, mainly 
in animal isolates (GALLAY et al., 2007; SAHIN et al., 2008; 
CHEN et al., 2010; LEHTOPOLKU et al., 2010; ADZITEY 
et al., 2012; CHOKBOONMONGKOL et al., 2013; DI 
GIANNATALE et al., 2014). Resistance to tetracycline 
has a clinical importance, since tetracycline is considered 
a second-line treatment for human Campylobacter spp. 
infections because of its low cost and toxicity (AARESTRUP 
et al., 2008; FITZGERALD et al., 2008). Furthermore, 
even though cattle are not considered the main sources of 
human campylobacteriosis, a recent study has demonstrated 
that their potential as source of infection in humans is 
underestimated (JONAS et al., 2015).
The obtained results showed a higher frequency 
of erythromycin resistance among C. coli strains, 
whereas it was less frequent among the tested C. jejuni 
and C. fetus strains. These findings are of public health 
importance as erythromycin is the first choice to treat 
human gastroenteritis caused by Campylobacter spp. 
(AARESTRUP et al., 2008; FITZGERALD et al., 2008). 
The higher incidence of erythromycin resistance among 
C. coli compared to other Campylobacter species may 
be due to the fact that the resistant C. coli strains were 
isolated from pigs, which are the only food animals for 
which erythromycin is allowed to be used as feed additive 
in Brazil (SILVA et al., 2013). Moreover, a higher frequency 
of erythromycin resistance has been reported worldwide 
among C. coli strains than C. jejuni strains (GIBREEL; 
TAYLOR, 2006; GALLAY et al., 2007; CHEN et al., 2010; 
LEHTOPOLKU et al., 2010).
For the tested aminoglycoside drugs, the findings were 
diverse. None of the tested Campylobacter spp. strains was 
resistant to gentamycin and only one C. coli was resistant 
to kanamycin (Figure 1). Susceptibility to gentamycin has 
been frequently described (LUANGTONGKUM et al., 
2007; MIRANDA; LAGE, 2007; LEHTOPOLKU et al., 
2010; ADZITEY et al., 2012; CHOKBOONMONGKOL et 
al., 2013; DI GIANNATALE et al., 2014; GIACOMELLI et 
al., 2014), being an important result, since gentamycin is 
commonly used in adherence and invasion assay (KONKEL; 
JOENS, 1989). Interestingly, the kanamycin susceptibility 
pattern observed in this study was also demonstrated 
to Campylobacter spp. strains also isolated in animals 
from Minas Gerais State, Brazil (MIRANDA; LAGE, 
2007). Kanamycin is not an antibiotic usually included in 
susceptibility tests, but, differently from the observed to 
Campylobacter spp. from Minas Gerais, Luangtongkum 
et al. (LUANGTONGKUM et al., 2007) observed 36.38% 
of resistance among Campylobacter spp. isolated from 
poultry. Although there is no breakpoint to streptomycin 
for either C. jejuni / C. coli or Enterobacteriaceae, the wide 
range of MIC values reported chiefly among C. jejuni 
and C. fetus strains (Figure 1) suggests that some strains 
may be resistant to this drug. However, it is important to 
consider that among the tested C. fetus strains the isolates 
from feces exhibited a wider MIC range (0.25 to 256 µg/
mL) than strains isolated from genital tract (0.25 to 4 µg/
mL), indicating that feces isolates had a greater tendency 
to streptomycin resistance. These results endorse the 
indication of streptomycin for treatment of bovine genital 
campylobacteriosis (LAGE; LEITE, 2000).
All of the C. jejuni and C. coli strains tested and most 
of the C. fetus strains were susceptible to chloramphenicol 
(Figure 1). This high susceptibility to chloramphenicol may 
be due to the prohibition of the use of this antibiotic in 
veterinary medicine in Brazil because of the risk of residues 
of this drug in meat, milk, and eggs (BRASIL, 1998). Hence, 
chloramphenicol as well as kanamycin and gentamycin 
could be suggested as options to treat human Campylobacter 
infections in Brazil. Likewise, the sulfonamides tested, 
sulfadizine and sulfamethoxazole, could be recommended 
to treat infections by Campylobacter spp., since they 
also demonstrated very good activity against C. jejuni, 
C. coli, and C. fetus strains isolated in Minas Gerais. As 
sulfonamides are not indicated for treatment of human or 
animal campylobacteriosis, they are usually not included 
in the antimicrobial susceptibility test for Campylobacter 
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spp., preventing any comparison with the present results. 
However, Italian C. jejuni and C. coli showed high rate 
of resistance to combination sulfamethoxazole plus 
trimethoprim (GIACOMELLI et al., 2014).
Besides the high rates of resistance to individual 
antimicrobial agents, the tested Campylobacter spp. 
strains from animal origin, mainly C. coli and C. fetus, 
also exhibited a high frequency of multidrug resistance. 
Considering that C. jejuni and C. coli are naturally 
resistant to cefoperazone, the erythromycin-tetracycline 
and nalidixic acid-tetracycline resistance patterns were 
the most frequent ones amongst the tested C. jejuni and 
C. coli. Quinolone-tetracycline concomitant resistance 
has also been described as one of the most prevalent in 
C. jejuni and C. coli strains from broilers, cattle, ducks, 
humans, and pigs in China, France, Finland, Italy, 
Malaysia, and Thailand (HAKANEN et al., 2003; GALLAY 
et al., 2007; CHEN et al., 2010; ADZITEY et al., 2012; 
CHOKBOONMONGKOL et al., 2013; DI GIANNATALE 
et al., 2014; GIACOMELLI et al., 2014). The tested C. 
fetus strains showed cefoperazone-tetracycline as the 
most common multidrug-resistance profile, taking into 
account that this species is naturally resistant to nalidixic 
acid. The present results were different from those observed 
by Miranda and Lage (2007) and Vargas et al. (2005) for 
Brazilian C. fetus isolates, which exhibited a low prevalence 
of multidrug resistant strains, with absence or low 
observation of resistance to tetracycline. These differences 
could be explained, considering that the multiple drug 
resistance observed was higher in C. fetus isolates from 
feces (57.14%) than from genital tract (28.57%), and that 
all C. fetus strains tested by Vargas et al. were from genital 
origin. Besides, differences in the methodology used or 
in the origin of the strains could also contribute to the 
differences detected. Efflux system conferring resistance 
to several classes of antimicrobials such as tetracyclines, 
macrolides, fluoroquinolones, and aminoglycosides has 
been widely described in Campylobacter spp. (GIBREEL; 
TAYLOR, 2006; FITZGERALD et al., 2008), and could be 
responsible for the multidrug resistance patterns observed.
In conclusion, it was found that the majority of C. 
jejuni, C. coli, and C. fetus strains isolated from different 
animal species in Brazil were sensitive to gentamycin, 
chloramphenicol, and sulfonamides. However, a high 
proportion of strains showed reduced susceptibility to 
nalidixic acid, ampicillin, cefoperazone, and tetracycline, 
antimicrobial agents commonly used for the treatment of 
human campylobacteriosis. Moreover, the high percentage 
of multidrug resistant strains observed among C. coli and 
C. fetus animal isolates confirms the need for continuous 
monitoring of Campylobacter spp. resistance in the pig and 
cattle production chains.
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